Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab for treating Osteogenesis Imperfecta [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc., and it includes purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff in the lawsuit [1][6]. - The lawsuit alleges that Ultragenyx misrepresented the reliability of data from its Phase III Orbit study, which failed to show a statistically significant reduction in annualized fracture rate [3]. Group 2: Allegations and Stock Impact - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. - The company attributed the study failures to a low fracture rate in the placebo group and a trend that did not reach statistical significance [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ultragenyx stock during the class period to seek lead plaintiff status [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - A class action lawsuit has been announced against Snowflake Inc. for securities fraud, involving purchasers of Class A common stock between June 27, 2023, and February 28, 2024, with the opportunity for investors to serve as lead plaintiffs [1]. Group 1: Lawsuit Details - The lawsuit claims that during the class period, Snowflake's management made positive statements about business performance while failing to disclose significant negative impacts on consumption and revenues due to product efficiency gains and pricing strategies [1]. - Investors who purchased Snowflake Class A common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - The Rosen Law Firm, which is leading the lawsuit, has a strong track record in securities class actions, having recovered hundreds of millions of dollars for investors in the past [1]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [1]. - A lead plaintiff must be appointed by April 27, 2026, to represent the interests of the class members in the litigation [1]. - Until a class is certified, investors are not represented by counsel unless they retain one, and they may choose to remain absent from the class [1].

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors regarding the FDA's response to its New Drug Application for relacorilant, leading to significant stock price decline [1][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, with a deadline for lead plaintiff motion set for April 21, 2026 [1]. - The lawsuit claims that Corcept made materially false and misleading statements and failed to disclose adverse facts about its business and prospects during the class period [4]. Group 2: FDA Response and Stock Impact - On December 31, 2025, the FDA issued a Complete Response Letter (CRL) declining to approve Corcept's NDA for relacorilant, stating that additional evidence of effectiveness was required [3]. - Following the FDA's announcement, Corcept's stock price dropped by $35.40 per share, or 50.42%, closing at $34.80 on December 31, 2025 [3]. Group 3: FDA Concerns - An updated CRL published on January 30, 2026, revealed that the FDA had previously expressed concerns about the adequacy of Corcept's clinical development program for relacorilant [4]. - The FDA indicated that significant review issues were expected if Corcept submitted its NDA, which was not disclosed to investors [4].

Core Insights - Insiders may receive substantial financial benefits not available to ordinary shareholders, raising concerns about potential conflicts of interest in proposed transactions [1] - Halper Sadeh LLC is investigating Masimo Corporation's sale to Danaher Corporation for $180.00 per share in cash for potential violations of federal securities laws and breaches of fiduciary duties [2] - Kennedy-Wilson Holdings, Inc. is being investigated regarding its sale to a consortium led by its Chairman and CEO for $10.90 per share in cash, also raising similar concerns [3] Company Investigations - Halper Sadeh LLC may seek increased consideration, additional disclosures, and other relief on behalf of shareholders affected by the transactions [4] - The firm represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - The article discusses a class action lawsuit against Corcept Therapeutics Incorporated, alleging violations of the Securities Exchange Act of 1934 related to the company's new drug application for relacorilant, which was not adequately supported by clinical evidence as claimed by the company [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated" and allows purchasers of Corcept common stock between October 31, 2024, and December 30, 2025, to seek appointment as lead plaintiff by April 21, 2026 [1]. - The lawsuit alleges that Corcept misrepresented the status of the relacorilant New Drug Application (NDA), claiming it was supported by strong evidence and was nearing approval, while the FDA had raised concerns about the clinical evidence [3][4]. - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the relacorilant NDA, stating that additional evidence of effectiveness was required, leading to a stock price drop of over 50% [4]. Group 2: FDA Concerns and Implications - The FDA's CRL, published on January 30, 2026, detailed concerns regarding the adequacy of clinical studies submitted for relacorilant, indicating that the evidence was insufficient for the proposed indication [5]. - The FDA had previously communicated concerns about the clinical development program to Corcept during pre-submission meetings, warning of potential significant review issues if the application was submitted [5]. Group 3: Legal Representation and Firm Background - Robbins Geller Rudman & Dowd LLP is representing investors in the class action lawsuit and is recognized as a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].

Core Viewpoint - The PayPal class action lawsuit alleges that the company and certain executives misled investors regarding the company's revenue outlook and growth potential during the Class Period, leading to significant financial losses for shareholders [3][4]. Group 1: Class Action Details - The lawsuit is titled Goodman v. PayPal Holdings, Inc., and it allows purchasers of PayPal common stock between February 25, 2025, and February 2, 2026, to seek appointment as lead plaintiff by April 20, 2026 [1]. - The lawsuit claims that PayPal's executives created a false impression of reliable growth projections while downplaying risks associated with seasonality and macroeconomic factors [3]. Group 2: Financial Performance and Impact - On February 3, 2026, PayPal announced disappointing financial results for Q4 and the full fiscal year 2025, which included a decline in Branded Checkout performance and the withdrawal of previously set 2027 financial targets [4]. - Following the announcement, PayPal's stock price fell by more than 20%, reflecting investor reaction to the negative news and the transition of CEO James Alexander Chriss [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased PayPal common stock during the Class Period to seek lead plaintiff status, which involves directing the class action lawsuit on behalf of all class members [5]. - The lead plaintiff can choose a law firm to represent them, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering a total of $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [6].

purchasers or acquirers of Richtech Robotics Inc. (NASDAQ: RR) publicly traded...][More Releases From This Source]## Explore[Banking & Financial Services][News Releases in Similar Topics]---- -- Kyndryl Holdings, Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 13, 2026 [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- The law firm of [Robbins Geller Rudman & Dowd LLP] announces that purchasers or acquirers of Kyndryl Holdings, Inc. (NYSE: KD) publicl ...

Core Viewpoint - Ademi LLP is investigating potential securities fraud claims against Driven Brands Holdings Inc. due to possible inaccuracies in its financial statements and business operations [1] Group 1: Investigation Details - The investigation is focused on whether Driven Brands had adequate controls and systems in place for financial reporting and accounting [1] - Driven Brands announced the discovery of major errors in its financial statements for the years 2023, 2024, and 2025, which will require restatements and delays in reporting [1]

Core Viewpoint - A class action lawsuit has been filed against Navan, Inc. for violations of federal securities laws, alleging that the company made false and misleading statements regarding its financial needs post-IPO [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors who purchased Navan's securities related to its IPO on October 31, 2025, and encourages them to contact the firm before April 24, 2026 [2]. - The lawsuit claims that Navan misled investors by not disclosing the need for significant increases in sales and marketing expenditures to achieve growth in usage yield and Gross Booking Volume [4]. Group 2: Investor Impact - Investors suffered damages when the truth about Navan's financial requirements became known, indicating that the company's public statements were materially misleading during the IPO period [4].

Core Viewpoint - The lawsuit against BellRing Brands, Inc. alleges that the company and its executives misled investors regarding the true drivers of its sales growth, which was primarily due to retailers hoarding inventory rather than genuine consumer demand [3][5]. Group 1: Allegations and Misleading Statements - The lawsuit claims that BellRing's reported sales growth in 2025 was not reflective of actual consumer demand but was instead driven by retailers stockpiling inventory to avoid previous supply chain shortages [3][8]. - It is alleged that once retailers felt secure about product availability, they began to destock their excess inventory, leading to a significant drop in BellRing's share price [3][8]. - The CFO of BellRing admitted that some retailers were hoarding inventory but downplayed the potential negative impact on sales, which resulted in a 19% drop in share price following the Q2 2025 financial results [8]. Group 2: Financial Impact and Market Reaction - Following the disappointing Q3 2025 financial results, BellRing's share price fell by 33% as the company reported a narrowed sales outlook and cited increasing competition as a factor [3][8]. - The lawsuit highlights that the strong sales reported during the class period were materially attributable to temporary inventory stockpiling rather than sustainable brand momentum [8]. Group 3: Legal Proceedings and Next Steps - The lead plaintiff deadline for the lawsuit is set for March 23, 2026, and investors who purchased shares between November 19, 2024, and August 4, 2025, are encouraged to submit their losses [6][7]. - Hagens Berman, the law firm handling the case, is actively investigating the claims and advising affected investors [6][10].